NVO's new U.S. pricing deal for Ozempic and Wegovy expands access but adds uncertainty to its growth and profit outlook.

The deal involves Eli Lilly, which makes Zepbound and Mounjaro, and Novo Nordisk, the maker of Ozempic and Wegovy. The drugs, known as GLP-1 medications, now cost as much as $1350 a month. Under the ...

Oral GLP-1 weight loss pills could replace injections by March 2026 at $150 monthly, Medicare chief Dr. Mehmet Oz predicted in a FOX Business appearance.

Those weight loss drugs that have been so out of reach for many, may soon be affordable, even if you don't have insurance.

The Trump administration has struck a deal to cut prices on popular weight loss drugs like Ozempic, expanding Medicare and Medicaid coverage to make them more affordable.

People taking GLP-1 meds could see costs drop in 2026, thanks to a new federal deal with Eli Lilly and Novo Nordisk, the ...

President Trump has announced a significant policy shift that allows Medicare to cover weight loss drugs such as Ozempic, ...

Novo Nordisk and Eli Lilly reached deals to lower GLP-1 drug costs for Medicare and Medicaid patients under Trump’s new ...

If Trump decides to go ahead and pursue a piece of Novo Nordisk, he would be under more public pressure to successfully lower ...

Novo Nordisk A/S & Eli Lilly and Company cut prices for top diabetes drugs, boosting accessibility and potential revenue.

The nationwide weight-loss goal Oz mentioned Thursday would be significantly more realistic if he intended to say 135 million ...

At a White House event Thursday, President Trump announced deals with drug makers Novo Nordisk and Eli Lilly to offer their ...